Print

Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/124/phase-1-study-of-oral-drug-pmd-026-in-people-with-metastatic-breast-cancer-and-metastatic-triple-negative-breast-cancer

Clinicaltrials.gov identifier:
NCT04115306 (https://clinicaltrials.gov/show/NCT04115306)


Study Contact Information:

For more information about the study, visit https://phoenixmd.ca/clinical-trials.

About the Study

PMD-026 is a study for people who have been diagnosed with metastatic triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC.  NOTE: This study is no longer enrolling. 

 

This Study is Open To:

NOTE: This study is no longer enrolling. 

This Study is Not Open To:

NOTE: This study is no longer enrolling. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.